We recently compiled a list of the 10 Firms Defy Market Pessimism. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other firms. Ten companies finished firmer on Friday,

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.

Novo Nordisk A/S rose the most since August 2023 after its experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.